ArticlePloS one2008
CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer.
Ranjan Chrisanthar et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
57 papers cite it
this papertrialcites it